ATE86858T1 - Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst. - Google Patents

Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.

Info

Publication number
ATE86858T1
ATE86858T1 AT86114795T AT86114795T ATE86858T1 AT E86858 T1 ATE86858 T1 AT E86858T1 AT 86114795 T AT86114795 T AT 86114795T AT 86114795 T AT86114795 T AT 86114795T AT E86858 T1 ATE86858 T1 AT E86858T1
Authority
AT
Austria
Prior art keywords
buspiron
relief
preparation
pharmaceutical compositions
morbid anxiety
Prior art date
Application number
AT86114795T
Other languages
English (en)
Inventor
Neil M Kurtz
Roger E Newton
Davis L Temple Jr
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE86858T1 publication Critical patent/ATE86858T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT86114795T 1985-10-25 1986-10-24 Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst. ATE86858T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/791,182 US4634703A (en) 1985-10-25 1985-10-25 Method for alleviation of panic disorders
EP86114795A EP0220696B1 (de) 1985-10-25 1986-10-24 Verwendung von Buspiron zur Herstellung von pharmazeutischen Zusammensetzungen zur Linderung von krankhaften Angst

Publications (1)

Publication Number Publication Date
ATE86858T1 true ATE86858T1 (de) 1993-04-15

Family

ID=25152914

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86114795T ATE86858T1 (de) 1985-10-25 1986-10-24 Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.

Country Status (11)

Country Link
US (1) US4634703A (de)
EP (1) EP0220696B1 (de)
JP (1) JPH0667841B2 (de)
AT (1) ATE86858T1 (de)
AU (1) AU592121B2 (de)
CY (1) CY1786A (de)
DE (1) DE3688038T2 (de)
ES (1) ES2053429T3 (de)
GR (1) GR3007393T3 (de)
HK (1) HK87094A (de)
ZA (1) ZA867670B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
DE3736974A1 (de) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg Verwendung von 2-pyrimidinyl-1-piperazin-derivaten
US5468749A (en) * 1988-08-30 1995-11-21 Gawin; Frank H. Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
US5166202A (en) * 1990-09-19 1992-11-24 Trustees Of The University Of Pennsylvania Method for the treatment of panic disorder
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
JPH04327532A (ja) * 1991-01-31 1992-11-17 Bristol Myers Squibb Co 活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5457100A (en) * 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
JPH08500577A (ja) * 1992-07-15 1996-01-23 ユニヴァーシティ オブ サウス フロリダ パニック障害の治療に関連するｃｃｋペプチドの血中濃度
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
WO1995009006A1 (en) * 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
US7588732B2 (en) * 2004-03-30 2009-09-15 Genesis Biosystems, Inc. Autologus tissue harvesting and irrigation device
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
DK2013835T3 (en) * 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20120077818A1 (en) * 2009-05-13 2012-03-29 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof
RU2660583C1 (ru) * 2017-08-15 2018-07-06 Общество С Ограниченной Ответственностью "Валента - Интеллект" Применение буспирона для лечения функционального головокружения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987052A (en) * 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4508726A (en) * 1982-09-16 1985-04-02 The Upjohn Company Treatment of panic disorders with alprazolam
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders

Also Published As

Publication number Publication date
DE3688038D1 (de) 1993-04-22
AU6424586A (en) 1987-04-30
US4634703A (en) 1987-01-06
DE3688038T2 (de) 1993-07-01
JPS62111924A (ja) 1987-05-22
CY1786A (en) 1995-10-20
JPH0667841B2 (ja) 1994-08-31
EP0220696A2 (de) 1987-05-06
ES2053429T3 (es) 1994-08-01
HK87094A (en) 1994-09-02
EP0220696B1 (de) 1993-03-17
GR3007393T3 (de) 1993-07-30
AU592121B2 (en) 1990-01-04
EP0220696A3 (en) 1989-10-04
ZA867670B (en) 1987-06-24

Similar Documents

Publication Publication Date Title
ATE86858T1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
DE3773057D1 (de) Vorrichtung zur kontrollierten abgabe von arzneimitteln, ihre zubereitung und verwendung.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE77557T1 (de) Zusammensetzung zur erhoehung der intrazell-atpspiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE219073T1 (de) Benzopyran derivate mit leukotrien- antagonistischer wirkung
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
NO893135D0 (no) Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater.
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE99945T1 (de) Verwendung von 5'-deoxy-5'-methylthioadenosin s- adenosylmethionin und dessen salzen zur herstellung von seborrhea vermindernden arzneimitteln.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
DE3771584D1 (de) Zusammensetzungen und anwendung von interleukin-2 und/oder interferon-beta und des tumor-necrosis-faktors fuer eine kombinationstherapie oder zur herstellung von arzneimitteln oder formulierungen.
DK144885A (da) Substituerede 4-hydroxybenzopyraner eller farmaceutisk acceptable additionssalte deraf, deres fremstilling og anvendelse som laegemidler
EP0161816A3 (de) Urogastrone
PT97052A (pt) Processo para a preparacao de composicoes farmaceuticas contendo bambuterol, apropriadas para diminuir o teor de lipidos no sangue
ATE112167T1 (de) Verwendung von gepiron für medikamente zur milderung panischer zustände.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
DE3788888D1 (de) Perhydrothiazepin- und Perhydroazepinderivate, ihre Herstellung und ihre therapeutische Verwendung.
ATE270098T1 (de) Wirkstoff enthaltende orale oder mucosale zubereitung mit steuerbarer wirkstofffreisetzung und ihre verwendung
IT1213568B (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ATE100803T1 (de) Perhydrothiazepin- und perhydroazepinderivate, ihre herstellung und ihre therapeutische verwendung.
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee